Q2 2026 13F · SEC CIK 1535610
Sabby Management, LLC
Hedge fundFiled 2026-08-14 for Q2 2026. Open the filing ↗ · All SEC filings ↗
- Reported 13F value
- $12.0M
- Reported positions
- 16
- Holdings vs S&P 500, 3 yrs
- —
- Average holding period
- 2 qtrs
Sabby Management, LLC is a hedge fund that reported 16 positions worth $12.0M in its Q2 2026 13F, filed 2026-08-14. Its largest holdings were State Str Spdr S&p 500 ETF T (SPY, 34.2%), Toyo Co Ltd (TOYO, 29.1%), Farmmi Inc (FAMI, 7.0%).
Sabby Management, LLC holdings all 16 positions.
Weights are shares of the filer's total reported 13F value, compared with Q1 2026. Share changes may reflect splits; weight changes also reflect price moves. A 13F shows long US-listed positions only, up to 135 days after the fact.
| Stock | % of 13F value | Share change | Reported value |
|---|---|---|---|
| SPYState Str Spdr S&p 500 ETF T | 34.2% | +101.2% | $4.1M |
| TOYOToyo Co Ltd | 29.1% | — | $3.5M |
| FAMIFarmmi Inc | 7.0% | — | $840K |
| CRVOCervomed Inc | 6.4% | — | $772K |
| 87978U207Tempest Therapeutics Inc | 4.7% | +2763.4% | $568K |
| G4289N155Paranovus Entertnmnt Tech Lt | 4.7% | — | $561K |
| 09076W307Bioaffinity Technologies | 2.5% | — | $297K |
| CREGSmart Power Corp | 2.2% | — | $263K |
| BCTXBriacell Therapeutics Corp | 2.2% | +9.2% | $262K |
| 76135L804Revelation Biosciences Inc | 1.8% | +111.8% | $217K |
| SNESSenestech Inc | 1.8% | -35.1% | $211K |
| BCTXLBriacell Therapeutics Corp | 1.4% | -50.0% | $169K |
| SIDUSidus Space Inc | 1.0% | — | $122K |
| INMInMed Pharmaceuticals Inc | 0.6% | -79.6% | $70K |
| 67113Y801Nuwellis Inc | 0.4% | — | $50K |
| BCTXZBriacell Therapeutics Corp | 0.1% | -41.6% | $11K |
What Sabby Management, LLC bought and sold in Q2 2026, against Q1 2026.
New positions
- TOYO Toyo Co Ltd29.1% of 13F
- FAMI Farmmi Inc7.0% of 13F
- CRVO Cervomed Inc6.4% of 13F
- Paranovus Entertnmnt Tech Lt4.7% of 13F
- Bioaffinity Technologies2.5% of 13F
- CREG Smart Power Corp2.2% of 13F
- SIDU Sidus Space Inc1.0% of 13F
- Nuwellis Inc0.4% of 13F
Added to
- Tempest Therapeutics Inc+2763.4% shares
- Revelation Biosciences Inc+111.8% shares
- SPY State Str Spdr S&p 500 ETF T+101.2% shares
- BCTX Briacell Therapeutics Corp+9.2% shares
Reduced
- INM InMed Pharmaceuticals Inc-79.6% shares
- BCTXL Briacell Therapeutics Corp-50.0% shares
- BCTXZ Briacell Therapeutics Corp-41.6% shares
- SNES Senestech Inc-35.1% shares
Sold out
- Alpha Compute Corpwas 11.5%
- DSY Big Tree Cloud Hldgs Ltdwas 5.9%
- TC Token Cat Ltdwas 4.2%
- Pop Culture Group Co Ltdwas 3.5%
- Moleculin Biotech Incwas 3.0%
- Biodexa Pharmaceuticals PLCwas 2.8%
- RKDA Arcadia Biosciences Incwas 2.8%
- TRX Trx Gold Corpwas 2.6%
Share counts compared with the Q1 2026 13F; a split also changes share counts.
How the holdings did against the S&P 500.
- 1 year
- —
- 3 years
- —
- 5 years
- —
A portfolio of the filer's 20 largest 13F positions, weighted by value, bought the trading day after each 13F was filed and held until the next one was: what copying this filer could have earned. 13Fs show long US-listed positions only, so this is an estimate of the stock picks, not the fund's reported returns.
Reported 13F value by quarter.
| Quarter | 13F value | Positions |
|---|---|---|
| Q2 2026 | $12.0M | 16 |
| Q1 2026 | $5.7M | 22 |
| Q4 2025 | $12.0M | 25 |
| Q3 2025 | $19.3M | 29 |
| Q2 2025 | $13.0M | 33 |
| Q1 2025 | $23.8M | 36 |
| Q4 2024 | $12.3M | 16 |
| Q3 2024 | $7.2M | 27 |
| Q2 2024 | $7.5M | 27 |
| Q1 2024 | $14.0M | 43 |
| Q4 2023 | $11.3B | 46 |
| Q3 2023 | $31.6M | 66 |
Questions about Sabby Management, LLC's portfolio
What stocks does Sabby Management, LLC own?
Sabby Management, LLC's latest 13F, for Q2 2026 and filed Aug 14, 2026, lists 16 positions worth $12.0M. The largest are State Str Spdr S&p 500 ETF T (SPY) at 34.2%, Toyo Co Ltd (TOYO) at 29.1%, Farmmi Inc (FAMI) at 7.0%, Cervomed Inc (CRVO) at 6.4% and Tempest Therapeutics Inc at 4.7%.
What did Sabby Management, LLC buy last quarter?
In Q2 2026, Sabby Management, LLC added a new position in Toyo Co Ltd (TOYO), a new position in Farmmi Inc (FAMI), a new position in Cervomed Inc (CRVO), a new position in Paranovus Entertnmnt Tech Lt, a new position in Bioaffinity Technologies, Tempest Therapeutics Inc (+2763.4% shares), Revelation Biosciences Inc (+111.8% shares) and State Str Spdr S&p 500 ETF T (SPY) (+101.2% shares), compared with its Q1 2026 filing.
What did Sabby Management, LLC sell last quarter?
In Q2 2026, Sabby Management, LLC sold all of Alpha Compute Corp, sold all of Big Tree Cloud Hldgs Ltd (DSY), sold all of Token Cat Ltd (TC), sold all of Pop Culture Group Co Ltd, sold all of Moleculin Biotech Inc, InMed Pharmaceuticals Inc (INM) (-79.6% shares), Briacell Therapeutics Corp (BCTXL) (-50.0% shares) and Briacell Therapeutics Corp (BCTXZ) (-41.6% shares), compared with its Q1 2026 filing.
When is Sabby Management, LLC's next 13F filing due?
13F filings are due 45 days after each quarter ends. Sabby Management, LLC's filing for the quarter ending Sep 30, 2026 is due by Nov 14, 2026; this page updates the day after it is published.